X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SUN PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SUN PHARMA SANOFI INDIA/
SUN PHARMA
 
P/E (TTM) x 33.6 24.4 137.9% View Chart
P/BV x 6.4 3.6 179.8% View Chart
Dividend Yield % 1.4 0.6 218.3%  

Financials

 SANOFI INDIA   SUN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
SUN PHARMA
Mar-17
SANOFI INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560842 541.5%   
Low Rs4,400572 768.7%   
Sales per share (Unadj.) Rs1,028.5131.6 781.4%  
Earnings per share (Unadj.) Rs129.032.7 394.3%  
Cash flow per share (Unadj.) Rs186.038.0 489.7%  
Dividends per share (Unadj.) Rs68.003.50 1,942.9%  
Dividend yield (eoy) %1.50.5 306.7%  
Book value per share (Unadj.) Rs753.6152.7 493.5%  
Shares outstanding (eoy) m23.032,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.45.4 81.1%   
Avg P/E ratio x34.721.6 160.6%  
P/CF ratio (eoy) x24.118.6 129.3%  
Price / Book Value ratio x5.94.6 128.4%  
Dividend payout %52.710.7 492.7%   
Avg Mkt Cap Rs m103,1741,696,877 6.1%   
No. of employees `0003.617.5 20.7%   
Total wages/salary Rs m3,59249,023 7.3%   
Avg. sales/employee Rs Th6,537.718,028.3 36.3%   
Avg. wages/employee Rs Th991.42,798.8 35.4%   
Avg. net profit/employee Rs Th819.84,479.5 18.3%   
INCOME DATA
Net Sales Rs m23,686315,784 7.5%  
Other income Rs m7086,232 11.4%   
Total revenues Rs m24,394322,016 7.6%   
Gross profit Rs m5,281100,893 5.2%  
Depreciation Rs m1,31312,648 10.4%   
Interest Rs m153,998 0.4%   
Profit before tax Rs m4,66190,479 5.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,69112,116 14.0%   
Profit after tax Rs m2,97078,462 3.8%  
Gross profit margin %22.331.9 69.8%  
Effective tax rate %36.313.4 270.9%   
Net profit margin %12.524.8 50.5%  
BALANCE SHEET DATA
Current assets Rs m15,673329,537 4.8%   
Current liabilities Rs m6,678178,870 3.7%   
Net working cap to sales %38.047.7 79.6%  
Current ratio x2.31.8 127.4%  
Inventory Days Days7679 96.2%  
Debtors Days Days2283 26.8%  
Net fixed assets Rs m8,098204,766 4.0%   
Share capital Rs m2302,399 9.6%   
"Free" reserves Rs m17,088363,997 4.7%   
Net worth Rs m17,356366,397 4.7%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m25,400614,102 4.1%  
Interest coverage x311.723.6 1,319.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.5 181.3%   
Return on assets %11.813.4 87.5%  
Return on equity %17.121.4 79.9%  
Return on capital %26.924.8 108.5%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14544,118 16.2%   
Fx outflow Rs m6,84624,484 28.0%   
Net fx Rs m29919,634 1.5%   
CASH FLOW
From Operations Rs m3,22670,822 4.6%  
From Investments Rs m-1,555-42,216 3.7%  
From Financial Activity Rs m-1,818-22,854 8.0%  
Net Cashflow Rs m-1476,107 -2.4%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 5.1 280.7%  
FIIs % 14.6 23.0 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   15,184 133,026 11.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 22, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - GSK PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS